|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
Clinical Significance of p53, c-erbB-2, Chromogranin A and PCNA in the Ampullary Carcinoma
Ki Hwan Kim, Sun Whe Kim, Woo Ho Kim, Yong Hyun Park
J Korean Cancer Assoc.
2001;33(1):84-91.
K-ras Mutation in Ampulla of Vater Cancer
Sang Jae Park, Sun Whe Kim, Woo Ho Kim, Jin Young Jang, Yong Hyun Park
J Korean Cancer Assoc.
2000;32(5):981-988.
The Effect of Adjuvant Therapy for Curatively Resected Extrahepatic Bile Duct Cancer
Won Shik Han, Sang Jae Park, Sun Whe Kim, Ki Hwan Kim, Sung Whan Ha, Yung Jue Bang, Noe Kyeong Kim, Yong Hyun Park
J Korean Cancer Assoc.
1999;31(6):1253-1260.
Significance of p53 overexpression in extrahepatic bile duct cancer
Sun Hee Kim, Woo Ho Kim, Yong Hyun Park
J Korean Cancer Assoc.
1993;25(6):873-877.
Significance of chromogranin-A expression in the bile duct cancer
Sun Whe Kim, Woo Ho Kim, Sam Je Cho, Yong Hyun Park
J Korean Cancer Assoc.
1993;25(4):501-506.
5-fluorouracil, epirubicin, cisplatin(FEP) and 5-fluorouracil, cisplatin(FP) combination chemotherapy for advanced pancreatic carcinoma
Ki Hyeong Lee, Won Ki Kang, Chang In Suh, Young Suk Park, Heung Tae Kim, Yoon Koo Kang, Hyo Jin Kim, Dae Seog Heo, Yung Jue Bang, Yong Bum Yoon, Noe Kyeong Kim, Yong Hyun Park
J Korean Cancer Assoc.
1991;23(2):315-322.
Establishment of SNU cell lines: november 1989-august 1990
Jae Gahb Park, You Me Jeon, Kyu Ju Park, Han Kwang Yang, Dong Young Noh, Sun Whe Kim, Seung Keun Oh, Kuhn Uk Lee, Yong Hyun Park, Kuk Jin Choe, Jin Pok Kim, Soo Tae Kim
J Korean Cancer Assoc.
1991;23(2):169-187.
1
Journal Impact Factor 4.1